NxStage Medical, Inc. (NXTM) Set to Announce Quarterly Earnings on Wednesday
NxStage Medical, Inc. (NASDAQ:NXTM) will be announcing its earnings results before the market opens on Wednesday, November 1st.
NxStage Medical (NASDAQ:NXTM) last announced its quarterly earnings data on Monday, August 7th. The medical device company reported ($0.03) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.03). NxStage Medical had a negative return on equity of 2.43% and a negative net margin of 1.33%. The firm had revenue of $92.20 million for the quarter, compared to analyst estimates of $96.47 million. During the same quarter in the prior year, the company posted ($0.03) earnings per share. NxStage Medical’s quarterly revenue was up .0% on a year-over-year basis. On average, analysts expect NxStage Medical to post $-0.06 EPS for the current fiscal year and $0.09 EPS for the next fiscal year.
NxStage Medical, Inc. (NASDAQ:NXTM) opened at 27.37 on Wednesday. The company’s 50-day moving average price is $27.64 and its 200-day moving average price is $25.92. The firm’s market cap is $1.81 billion. NxStage Medical, Inc. has a one year low of $20.45 and a one year high of $30.80.
Several brokerages have weighed in on NXTM. Zacks Investment Research raised NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 target price on the stock in a research note on Thursday, August 10th. Canaccord Genuity cut NxStage Medical from a “buy” rating to a “hold” rating and set a $30.00 price target on the stock. in a research report on Monday, August 7th. BidaskClub cut NxStage Medical from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Craig Hallum cut NxStage Medical from a “buy” rating to a “hold” rating in a research report on Monday, August 7th. Finally, BTIG Research cut NxStage Medical from a “buy” rating to a “neutral” rating in a research report on Friday, August 11th. Two research analysts have rated the stock with a sell rating and eight have given a hold rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $30.25.
In related news, President Joseph E. Turk, Jr. sold 24,000 shares of NxStage Medical stock in a transaction on Monday, August 7th. The stock was sold at an average price of $29.64, for a total transaction of $711,360.00. Following the completion of the sale, the president now owns 82,903 shares of the company’s stock, valued at $2,457,244.92. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, President Joseph E. Turk, Jr. sold 7,000 shares of NxStage Medical stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $22.98, for a total value of $160,860.00. Following the sale, the president now directly owns 82,903 shares of the company’s stock, valued at approximately $1,905,110.94. The disclosure for this sale can be found here. In the last ninety days, insiders sold 49,600 shares of company stock valued at $1,398,382. 4.70% of the stock is currently owned by insiders.
About NxStage Medical
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.